Previous studies have shown that MET was significantly associated with the prognosis of immune “hot” and “cold” pancreatic cancer and the combined application of MET inhibition and PD-L1 blockade showed a significant therapeutic efficacy [21]. The gene discussed is CD274; the disease is pancreatic neoplasm.